Drugs / BNT112
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04382898 | Dec 2019 → Jan 2024 | prostate cancer | BioNTech SE | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04382898 ↗ |
| Known as | W_pro1 | “First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 (BNT112) Monotherapy” NCT04382898 ↗ |
| Route | Intravenous | “Intravenous bolus injection” NCT04382898 ↗ |